One year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • K Reich, Dermatologikum Hamburg & Georg-August-University, Göttingen, Germany.
  • ,
  • L Puig
  • ,
  • C Paul
  • ,
  • K Kragballe, Denmark
  • T Luger
  • ,
  • J Lambert
  • ,
  • S Chimenti
  • ,
  • G Girolomoni
  • ,
  • J-F Nicolas
  • ,
  • E Rizova
  • ,
  • M Brunori
  • ,
  • S Mistry
  • ,
  • P Bergmans
  • ,
  • J Barker
There are limited long-term, "real-world" data on ustekinumab, or the effect of dose adjustment in suboptimal responders.
Original languageEnglish
JournalBritish Journal of Dermatology
ISSN0007-0963
DOIs
Publication statusPublished - 30 Sep 2013

See relations at Aarhus University Citationformats

ID: 69017971